<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01516944</url>
  </required_header>
  <id_info>
    <org_study_id>TOTTG030103</org_study_id>
    <nct_id>NCT01516944</nct_id>
  </id_info>
  <brief_title>Perioperative Chemotherapy for Potentially Resectable Gastric Cancer</brief_title>
  <official_title>Perioperative Tegafur Gimeracil Oteracil Potassium Capsule Plus Oxaliplatin Versus Capecitabine Plus Oxaliplatin in Patients With Localized Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stage I：Neoadjuvant therapy

        -  Tegafur，Gimeracil and Oteracil Potassium Capsules plus oxaliplatin is superior to
           surgery alone;Capecitabine plus oxaliplatin is non-inferiority to Tegafur，Gimeracil and
           Oteracil Potassium Capsules plus oxaliplatin

      Stage II: Perioperative therapy

        -  Perioperative Tegafur，Gimeracil and Oteracil Potassium Capsules plus oxaliplatin is
           superior to adjuvant Tegafur，Gimeracil and Oteracil Potassium Capsules plus oxaliplatin
           alone;Capecitabine plus oxaliplatin regimen is noninferiority to Tegafur,Gimeracil and
           Oteracil Potassium Capsules plus oxaliplatin

        -  A regimen of Tegafur，Gimeracil and Oteracil Potassium Capsules plus oxaliplatin(SOX) and
           Capecitabine plus oxaliplatin(XELOX) improves survival among patients with incurable
           locally advanced or metastatic gastric cancer. The investigators assessed whether the
           addition of a perioperative regimen of SOX or XELOX regimen to adjuvant alone improves
           R0 resection rate and survival among patients with curable locally advanced gastric
           cancer.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival(DFS)</measure>
    <time_frame>3 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>At the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>At the end of the study</time_frame>
    <description>To Assess disease control rate (DCR) as defined CR + PR + SD assessed by RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Down staging rate</measure>
    <time_frame>Within 3 weeks after surgery</time_frame>
    <description>After the pathological examination of resected specimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Side effects during observation</time_frame>
    <description>Investigators graded all adverse events and toxic effects according to the National Cancer Institute's Common Toxicity Criteria, version 2.0. The number of Participants with adverse events will be recorded at each treatment visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0-resection rate</measure>
    <time_frame>Within 3 weeks after surgery</time_frame>
    <description>After the pathological examination of resected specimen</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">729</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>postoperative chemotherapy,SOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Perioperative chemotherapy,SOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Perioperative chemotherapy,XELOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin</intervention_name>
    <description>Tegafur，Gimeracil and Oteracil Potassium Capsules 80 mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for six cycles postoperation</description>
    <arm_group_label>postoperative chemotherapy,SOX</arm_group_label>
    <other_name>S-1</other_name>
    <other_name>Oxaliplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin</intervention_name>
    <description>Tegafur，Gimeracil and Oteracil Potassium Capsules 80mg/㎡ ,D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for two cycles preoperation, Tegafur，Gimeracil and Oteracil Potassium Capsules ,80 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for six cycles postoperation</description>
    <arm_group_label>Perioperative chemotherapy,SOX</arm_group_label>
    <other_name>S-1</other_name>
    <other_name>Oxaliplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin; Capecitabine</intervention_name>
    <description>Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for two cycle pre-operation, Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/m2 D1 q3wk for six cycles postoperation</description>
    <arm_group_label>Perioperative chemotherapy,XELOX</arm_group_label>
    <other_name>Oxaliplatin</other_name>
    <other_name>Capecitabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 -75

          -  Histologically or cytologically proven in operable advanced gastric adenocarcinoma
             (including adenocarcinoma of the gastrooesophageal junction)

          -  ECOG performance status ≦2

          -  Tumor stage T3/4NxM0

          -  No distant metastasis (M0)

        Exclusion Criteria:

          -  History of hypersensitivity to fluoropyrimidines, Tegafur，Gimeracil and Oteracil
             Potassium Capsules , capecitabine, oxaliplatin or the ingredients of this product

          -  Inadequate hematopoietic function： WBC≦4,000/mm3; ANC≦2,000/mm3; Platelet≦100,000/mm3

          -  Inadequate organ function which is defined as below:

        Total bilirubin &gt;2 pper limit of normal range (ULN); ALT / AST &gt; 2.5 upper limit of normal
        range (ULN) (&gt;5.0 x ULN if hepatic metastasis); serum creatinine &gt; 1.2 mg/dL, and Ccr &gt; 60
        ml/min (estimated by Cockcroft-Gault formulation);

          -  Symptomatic peripheral neuropathy

          -  Receiving a concomitant treatment with other fluoropyrimidines

          -  Pregnancy or lactation women, or women with suspected pregnancy or men unless using a
             reliable and appropriate contraceptive method.

          -  Mental status is not fit for chemotherapy therapy presence of serious concomitant
             illness which might be aggravated by study medication:

          -  Active cardiac disease e.g. decompensate myocardial infarction within the 6-month
             period preceding entry into the study.

          -  History of ventricular arrhythmia or congestive heart failure.

          -  Significant co-morbid medical conditions, including, but not limited to, Chronic
             obstructive pulmonary disease, interstitial pneumonia ,pulmonary fibrosis, heart
             failure, renal failure, hepatic failure, haemorrhagic peptic ulcer, mechanical or
             paralytic ileus, or poorly controlled diabetes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qun Zhao, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebei Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of General Surgery</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2012</study_first_submitted>
  <study_first_submitted_qc>January 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2012</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hebei Medical University</investigator_affiliation>
    <investigator_full_name>Qun Zhao</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Tegafur，Gimeracil and Oteracil Potassium Capsules</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>perioperative Chemotherapy</keyword>
  <keyword>Gastric Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Tegafur</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

